Physician profile
Young J Lee
NPI 1528036498
$3,002.83
in general payments reported to CMS, 2019-2025
30 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2021: $50.82 · 2022: $207 · 2023: $325 · 2024: $717 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $739.25 | 2019-2025 | Enhertu |
| Gilead Sciences, INC. | $233.51 | 2023-2025 | Trodelvy |
| Merz North America, INC. | $232.06 | 2024-2025 | |
| Janssen Biotech, INC. | $200.17 | 2024-2025 | Tecvayli, Darzalex, Talvey |
| Pfizer INC. | $177.16 | 2023-2025 | |
| Dermavant Sciences, INC. | $166.88 | 2023-2024 | Vtama |
| Glaxosmithkline, LLC. | $131.25 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Incyte Corporation | $124.76 | 2022-2025 | Jakafi |
| Merck Sharp & Dohme LLC | $100.32 | 2025 | Keytruda, Lynparza |
| Lilly USA, LLC | $90.10 | 2023-2025 | Jaypirca, Verzenio |
| Seagen INC. | $79.99 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $78.95 | 2021-2022 | |
| Genentech USA, INC. | $70.46 | 2023-2025 | Phesgo, Perjeta, Itovebi |
| Genentech, INC. | $52.21 | 2019 | |
| Tersera Therapeutics LLC | $50.56 | 2025 | Xermelo, Zoladex |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $44.83 | 2025 | |
| Adc Therapeutics America, INC. | $44.12 | 2025 | |
| Mirati Therapeutics, INC. | $41.41 | 2023-2024 | Krazati |
| Iovance Biotherapeutics, INC. | $37.91 | 2025 | Amtagvi |
| Regeneron Healthcare Solutions, INC. | $37.28 | 2023 | Libtayo |
| Pharmaessentia USA Corporation | $32.67 | 2025 | Besremi |
| Coherus Oncology, INC. | $30.37 | 2025 | Loqtorzi |
| Eisai INC. | $29.74 | 2025 | |
| Taiho Oncology, INC. | $28.34 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.97 | 2025 | Iclusig |
| Sobi, INC | $26.21 | 2025 | |
| Biocon Biologics INC | $25.89 | 2024 | Ogivri |
| Corcept Therapeutics | $25.54 | 2025 | Korlym |
| Azurity Pharmaceuticals, INC. | $23.21 | 2025 | Danziten |
| Novartis Pharmaceuticals Corporation | $19.71 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.